FDA Places Clinical Hold on Phase 2 LN-145 NSCLC Trial Enrollment

1 year ago 51

Patients with non–small cell lung cancer who already received LN-145 in the phase 2 IOV-LUN-202 trial will be followed per trial protocol following the FDA’s clinical hold.

1. Homepage
2. Lung Cancer
3. FDA Places Clinical Hold on Phase 2 LN-145 NSCLC Trial Enrollment